ArticleACS medicinal chemistry letters2018
C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?
Article in ACS medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Design, Synthesis, Antiproliferative Potency and In Silico Studies of Novel Alkynyl Quinazolines as Potential EGFR Inhibitors.International journal of molecular sciences · 2026Article
- A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non-small cell lung cancer (NSCLC).Science advances · 2026Article
- Covalent Alkynylpyridopyrimidinones Targeting Cysteine 775 of the Epidermal Growth Factor Receptor Overcome Resistance to Current Therapies.Journal of medicinal chemistry · 2026Article
- A neuregulin-like ligand and EGF receptor underpinFrontiers in cellular and infection microbiology · 2026Article
- Insight into the Anticancer Potential of Imidazole-Based Derivatives Targeting Receptor Tyrosine Kinases.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Impact of trifluoromethyl Ugi adducts as anticancer agents: EGFR inhibition, apoptosis induction and miRNA up-regulation.RSC advances · 2025Article
- Engineering IGF2 for Lysosome-targeting chimeras development to target drug-resistant membrane proteins in tumor therapy.Protein science : a publication of the Protein Society · 2025Article
- Screening of multi deep learning-based de novo molecular generation models and their application for specific target molecular generation.Scientific reports · 2025Article
- The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.Current medicinal chemistry · 2025Review
- Design and investigation of interactions of novel peptide conjugates of purine and pyrimidine derivatives with EGFR and its mutant T790M/L858R: an in silico and laboratory study.Molecular diversity · 2024Article
- The value of protein allostery in rational anticancer drug design: an update.Expert opinion on drug discovery · 2024Review
- DB-1310, an ADC comprised of a novel anti-HER3 antibody conjugated to a DNA topoisomerase I inhibitor, is highly effective for the treatment of HER3-positive solid tumors.Journal of translational medicine · 2024Article
- A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase.RSC medicinal chemistry · 2023Article
- Addressing the Osimertinib Resistance Mutation EGFR-L858R/C797S with Reversible Aminopyrimidines.ACS medicinal chemistry letters · 2023Article
- Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents.Journal of chemical information and modeling · 2023Article
- Atropisomerism in the Pharmaceutically Relevant Realm.Accounts of chemical research · 2022Article
- Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations.Biomolecules & therapeutics · 2022Review
- Design, synthesis, and in vitro antitumor activity of 6-aryloxyl substituted quinazoline derivatives.Turkish journal of chemistry · 2022Article
- Recent advances in the development of covalent inhibitors.RSC medicinal chemistry · 2021Review
- Design and Synthesis of Non-Covalent Imidazo[1,2-Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first evidence of osimertinib resistance mediated by the epidermal growth factor receptor (EGFR) mutation C797S was reported three years ago. Since then, no major breakthroughs have been achieved to target the clinically relevant mutant variant that impedes covalent bond formation with irreversible EGFR inhibitors. Although several biochemically active compounds have been described, only a few inhibitors that potently act on the cellular level or
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.